普通外文研报
Drug Supply Chain: Transparent Pressure: Thoughts on UNH PBM News
研报英文原文证据摘录
Drug Supply Chain: Transparent Pressure: Thoughts on UNH PBM News
Deutsche Bank
Research
North America Industry Date
United States 12 May 2026
Drug Supply Chain
Health Care Industry Update
Healthcare Technology &
Distribution
Transparent Pressure: Thoughts on
UNH PBM News
George Hill
UNH Launching Fee-based PBM Model: Optum Rx announced the launch of
Research Analyst
"Transparent Pharmacy Care Model" this week, which replaces traditional PBM +1-212-250-7822
pricing structures tied to manufacturer list prices and prescription volume with
fixed, clearly disclosed per-member service fees. The model eliminates spread Maxi Ma, CFA
Research Associate
pricing practices, provides clients visibility into Optum Rx and GPO-related fees,
+1-901-338-2175
and includes a commitment to transition group purchasing economics to flat
service fees by the end of 2027. The new cost-based pricing applies to all drugs and Liz Li
pharmacies instead of a small subset, and Optum customers can audit the rebates Research Associate
and fees all the way to the GPO Emisar. The structural change is complemented by +1-617-251-2782
new digital affordability tools, including “Shop MyScript” and “Price Wise,” which
Key Changes
allow consumers to compare medication costs, pharmacy options and delivery
choices before prescriptions are filled. The announcement builds on several recent Company Target Price Rating
Optum Rx initiatives focused on rebate pass-through, reducing both drug and UNH.N 360.00 to -
370.00
medical prior authorizations and restructuring pharmacy reimbursement terms.
The move follows similar transparent PBM model launches from peers, including Source: Deutsche Bank
CVS Caremark’s “TrueCost” initiative introduced in 2024 and Express Scripts’
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器